Cambridge Antibody Technology Company Profile

22:35 EDT 20th June 2018 | BioPortfolio

Cambridge Antibody Technology (CAT) is a biopharmaceutical company committed to developing human monoclonal antibody therapeutics to bring improvements to seriously ill patients' lives.CAT has strong financial foundations, good medium term prospects and significant opportunities for growth in the longer term.


Milstein BuildingGranta Park
United Kingdom


Phone: 44 (0)1223 471 471
Fax: 44 (0)1223 471 472

News Articles [842 Associated News Articles listed on BioPortfolio]

Could a new antibody screening method lead to better drugs?

Antibody proteins have been the fastest-growing class of approved drugs over the last two decades, but current antibody drug discovery...Read More... The post Could a new antibody screening method lea...

Cambridge Enterprise: How Apollo Therapeutics is driving forward therapeutic innovation.

Iain Thomas, Head of Life Sciences at Cambridge University’s technology transfer arm, discusses the recent launch of Apollo Therapeutics, an ambitious collaboration between AstraZeneca, GlaxoSmithK...

Cullinan Oncology and MAB Discovery Collaborate on Novel Antibody Therapeutics

US Cullinan Oncology, based in Cambridge, MA, and German MAB Discovery (MABD) announced the initiation of a collaboration to develop novel antibody therapeutics based on MABD's discovery platform.

AdipoGen Life Sciences anti-α-Tubulin, recombinant antibodies

AdipoGen Life Sciences’ anti-α-Tubulin monoclonal antibodies (recombinant) are composed of human variable regions (VH and VL) (λ-chain) of immunoglobulin fused to the human lgG2 Fc domain. anti-...

ProBioGen & Surface Oncology sign second antibody development project

German service and technology provider, ProBioGen, and immune-oncology company, Surface Oncology, have signed a second antibody development project for the development and manufacture of another antib...

Antibody Subtype Attacks Flu Viruses from Two Sides

The tips of an antibody’s two arms usually constitute the antibody’s “business end,” but sometimes the antibody’s tail matters, too. Both arm tips and the tail, it turns out, may engage the ...

4-Antibody: reshaping an antibody platform company and adding pipeline for a successful exit

In this episode of PharmaTelevision News Review, Fintan Walton talks to Robert Burns, CEO of 4-Antibody AG

IONTAS to Generate Antibodies using Mammalian Display Technology for a Global Biopharma.

IONTAS to generate antibodies with favourable, binding and expression properties using their Mammalian Display Antibody Discovery Platform Cambridge, UK, 22 January 2018: IONTAS Limited (IONTAS...

PubMed Articles [1806 Associated PubMed Articles listed on BioPortfolio]

Integration of Antibody Array Technology into Drug Discovery and Development.

Antibody arrays represent a high-throughput technique that enables the parallel detection of multiple proteins with minimal sample volume requirements. In recent years, antibody arrays have been widel...

Barcoded sequencing workflow for high throughput digitization of hybridoma antibody variable domain sequences.

Since the invention of Hybridoma technology by Milstein and Köhler in 1975, its application has greatly advanced the antibody discovery process. The technology enables both functional screening and l...

Toward rational antibody design: recent advancements in molecular dynamics simulations.

Because antibodies have become an important therapeutic tool, rational antibody design is a challenging issue involving various science and technology fields. From the computational aspect, many types...

Significant Drying Time Reduction using Microwave-Assisted Freeze-Drying for a Monoclonal Antibody.

Microwave-assisted freeze-drying is a rapid drying process well-known in food technology. However, little is known about its application to biologicals. In this study, we investigated the applicabilit...

Health Care For 1.4 Billion China's Healthcare System And Reform Edited by Lawton Robert Burns and Gordon G. Liu Cambridge (UK) : Cambridge University Press , 2017 482 pp., $125.00.

Clinical Trials [2871 Associated Clinical Trials listed on BioPortfolio]

Analysis of Biopsies With Antibody Mediated Rejection According to the Therapy Response

In adult kidney transplant recipients a therapy-responder and non-responder phenotype by antibody mediated rejection will be precisely defined according to clinical and histological charac...

User Evaluation of the Peristomal Skin Condition in Ostomates Using ConvaTec Moldable Technology™

The primary aim of this study is to demonstrate the maintenance of healthy peri-stomal skin over a two month period in subjects who use ConvaTec Moldable Technology™ Skin Barriers as par...

JCV Antibody Program (STRATIFY-1)

Study conducted to define the prevalence of Serum JC Antibody in relapsing MS patients receiving Tysabri or being considered for such treatment. Analytically validate the JCV antibody ass...

Expanded Access Study of Iodine-131 Anti-B1 Antibody

The primary objective of this study is to make Iodine-131 Anti-B1 Antibody more broadly available to patients. Secondary endpoints of the study will be to obtain additional information on...

JCV Antibody Program (STRATIFY-2)

Define the sero prevalence of JCV Antibody in the MS population and potentially stratify patients into lower or higher risk for developing PML based on antibody status.

Companies [1219 Associated Companies listed on BioPortfolio]

Cambridge Antibody Technology

Cambridge Antibody Technology (CAT) is a biopharmaceutical company committed to developing human monoclonal antibody therapeutics to bring improvements to seriously ill patients' lives.CAT has strong ...

Granta Park Ltd

Granta Park has established itself as the leading research park in the Cambridge sub-region. Concentrating on the life sciences it has attracted many of the foremost businesses in the field, including...

Cambridge Antibody Technology Group plc

The foundation of CAT's business is its unique antibody technologies, which it continues to develop and exploit. Based on this, CAT has established a position as a world leader, exploiting the charact...

Domantis Inc

Domantis Limited was launched in December 2000 by Sir Gregory Winter and Dr Ian Tomlinson of the MRC–LMB with the backing of the MRC and MVM Limited to commercialise Domain Antibody products. To dat...

Zenyth Therapeutics Limited

Zenyth Therapeutics Limited (Zenyth) is a public listed (ASX: ZTL) Australian biotechnology company primarily focused on the development and commercialisation of antibody-based therapies in the areas ...

More Information about "Cambridge Antibody Technology" on BioPortfolio

We have published hundreds of Cambridge Antibody Technology news stories on BioPortfolio along with dozens of Cambridge Antibody Technology Clinical Trials and PubMed Articles about Cambridge Antibody Technology for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Cambridge Antibody Technology Companies in our database. You can also find out about relevant Cambridge Antibody Technology Drugs and Medications on this site too.

Quick Search


Corporate Database Quicklinks

Searches Linking to this Company Record